Loading clinical trials...

COMPLETEDPHASE1

Dose Escalation Radiotherapy With Modulation of Intensity and Integrated Boost (SIB-IMRT) in the Treatment of Glioblastomas in Adults

Dose Escalation Radiotherapy With Modulation of Intensity and Integrated Boost in Association With a Temozolomide in the Treatment of Glioblastoma

NCT01043536•Centre Georges Francois Leclerc

View on ClinicalTrials.gov

Summary

The main goal of this study is to evaluate and to determine the dose of a highly accurate irradiation (allowing to increase the dose delivered while restricting the risk of complication) in association with temozolomide.

Eligibility

Age

18 - 70 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Histopathologically proven diagnosis of glioblastoma (WHO grade IV astrocytoma)
•Diagnosis must be obtained by a stereotactic or surgical biopsy
•Age between 18 and 70
•Total or partial surgical resection deemed as not possible by a neurosurgeon
•OMS performance status 0 or 1
•Adequate blood function : absolute neutrophil count \> 1.5 x 109/L, platelets count \> 100 x 109/L platelets;
•Adequate liver function: bilirubin \< 1.5 ULN (upper limit of normal), ALT and AST \< 3 ULN,
•Adequate renal function: creatinine \< 1.5 ULN
•Patient must have been informed and must have signed the specific informed consent form.

Exclusion Criteria

•other malignancy histology
•resection of the brain tumor complete on MRI exploration
•patient unable to give informed consent
•patient presenting counter-indication to MRI exploration
•patient must not have received neither radiotherapy nor chemotherapy for that affection
•concomitant malignancy
•patient already enrolled in another biomedical study with an experimental molecule
•pregnant, nursing woman, or without contraception
•private individuals of freedom or under tutelage (including legal guardianship)
•psychiatric, behavioural disorders or geographical situation precluding the administration or follow-up of the protocol (including claustrophobia)

Locations (1)

Centre Georges François Leclerc

Dijon, Bourgogne-Franche-Comté, France

Key Dates

Start Date

September 1, 2009

Primary Completion Date

January 1, 2012

Last Updated

September 25, 2012

Enrollment

ACTUAL participants

Conditions

Glioblastoma

Interventions

radiotherapy

RADIATION

temozolomide

DRUG

Targeted Pediatric High-Grade Glioma Therapy

NCT05839379

High Grade GliomaDiffuse Intrinsic Pontine Glioma+7 more

View study

RECRUITING

Collection of Blood and Urine Samples in Patients Receiving Radiation Therapy for Glioblastoma Multiforme

NCT00083512

Glioblastoma Multiforme

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: September 25, 2012Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Dose Escalation Radiotherapy With Modulation of Intensity and Integrated Boost (SIB-IMRT) in the Treatment of Glioblastomas in Adults

Inclusion Criteria

Exclusion Criteria

Targeted Pediatric High-Grade Glioma Therapy

Collection of Blood and Urine Samples in Patients Receiving Radiation Therapy for Glioblastoma Multiforme

Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma

Hypofractionation Trial of Re-irradiation in Good Prognosis Recurrent Glioblastoma

EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma

Study of TLX101-Tx Plus Standard of Care (SoC) Versus SoC Alone for the Treatment of Patients With Recurrent Glioblastoma